Table 3 Logistic regression analysis for factors’ association with improvement on anxiety stratified by anxiety at admission
From: Emergency palliative cancer care: anxiety and midazolam
Moderate and severe anxiety at admission (n = 62) | Univariate model | Multivariate model | ||
|---|---|---|---|---|
Factor (n)* | OR (95% CI) | P-value | OR (95% CI) | P-value |
Age | 1.02(0.98–1.07) | 0.322 | 1.01 (0.95–1.06) | 0.812 |
Gender | ||||
Female (18) | 1.49(0.45–4.93) | 0.518 | 2.89 (0.57–14.68) | 0.201 |
Marital status | ||||
Married (42) | Ref. | Ref. | ||
Living alone (20) | 1.85 (0.56–6.06) | 0.312 | 2.36 (0.44–12.74) | 0.317 |
Benzodiazepine treatment during stay | ||||
No treatment (23) | Ref. | Ref. | ||
Unchanged (16) | 0.78 (0.19–3.18) | 0.725 | 0.56 (0.10–3.23) | 0.514 |
Started/increased oral benzodiazepines (9) | 1.24 (0.20–7.67) | 0.821 | 1.41 (0.16–12.53) | 0.759 |
Started/increased subcutaneous midazolam (14) | 0.26 (0.06–1.08) | 0.065 | 0.24 (0.04–1.46) | 0.122 |
Opioid treatment during stay | ||||
No (22) | Ref. | Ref. | ||
Dose increased (30) | 0.56 (0.17–1.85) | 0.343 | 1.43 (0.26–7.83) | 0.677 |
Dose decreased (10) | 0.88 (0.17–4.54) | 0.874 | 1.99 (0.18-22.00) | 0.575 |
Improved analgesia | ||||
No (30) | Ref. | Ref. | ||
Yes (32) | 0.95 (0.33–2.74) | 0.931 | 0.85 (0.21–3.46) | 0.816 |
Improved dyspnoea | ||||
No (30) | Ref. | Ref. | ||
Yes (32) | 4.33 (1.39–13.55) | 0.012 | 6.64 (1.67–26.39) | 0.007 |
Mild anxiety at admission (n = 57) | Univariate model | Multivariate model | ||
Factor (n)* | OR (95% CI) | P-value | OR (95% CI) | P-value |
Age | 1.02(0.98–1.07) | 0.242 | 1.06 (1.00-1.14) | 0.067 |
Gender | ||||
Female (25) | 0.56(0.19–1.64) | 0.292 | 0.56 (0.12–2.67) | 0.469 |
Marital status | ||||
Married (34) | Ref. | Ref. | ||
Living alone (23) | 0.97 (0.34–2.83) | 0.962 | 1.14 (0.21–6.20) | 0.883 |
Benzodiazepine treatment during stay | ||||
No treatment (31) | Ref. | Ref. | ||
Unchanged (13) | 0.87 (0.23–3.26) | 0.831 | 0.95 (0.13–7.04) | 0.960 |
Started/increased oral benzodiazepines (6) | 2.77 (0.44–17.46) | 0.278 | 3.47 (0.38–31.72) | 0.271 |
Started/increased subcutaneous midazolam (7) | 1.04 (0.20–5.45) | 0.964 | 4.03 (0.39–41.58) | 0.242 |
Opioid treatment during stay | ||||
No (23) | Ref. | Ref. | ||
Dose increased (28) | 1.17 (0.38–3.59) | 0.788 | 1.17 (0.19–7.20) | 0.869 |
Dose decreased (6) | 3.11 (0.47–20.65) | 0.240 | 8.52 (0.76–96.03) | 0.083 |
Improved analgesia | ||||
No (22) | Ref. | Ref. | ||
Yes (35) | 1.65 (0.55–4.93) | 0.367 | 2.49 (0.46–13.49) | 0.291 |
Improved dyspnoea | ||||
No (27) | Ref. | Ref. | ||
Yes (30) | 4.29 (1.39–13.25) | 0.012 | 9.13 (1.89–44.16) | 0.006 |